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Abstract
Introduction: The objective of this study is to identify circulating microRNAs that distinguish
fast-progressing radiographic knee osteoarthritis (OA) in the Osteoarthritis Initiative cohort by
applying microRNA-sequencing.
Methods: Participants with Kellgren–Lawrence (KL) grade 0/1 at baseline were included
(N = 106). Fast-progressors were defined by an increase to KL 3/4 by 4-year follow-up (N = 20),
whereas slow-progressors showed an increase to KL 2/3/4 only at 8-year follow-up (N = 35).
Non-progressors remained at KL 0/1 by 8-year follow-up (N = 51). MicroRNA-sequencing was
performed on plasma collected at baseline and 4-year follow-up from the same participants.
Negative binomial models were fitted to identify differentially expressed (DE) microRNAs.
Penalized logistic regression (PLR) analyses were performed to select combinations of
DE microRNAs that distinguished fast-progressors. Area under the receiver operating
characteristic curves (AUC) were constructed to evaluate predictive ability.
Results: DE analyses revealed 48 microRNAs at baseline and 2 microRNAs at 4-year
follow-up [false discovery rate (FDR) < 0.05] comparing fast-progressors with both slowprogressors and non-progressors. Among these were hsa-miR-320b, hsa-miR-320c,
hsa-miR-320d, and hsa-miR-320e, which were predicted to target gene families, including
members of the 14-3-3 gene family, involved in signal transduction. PLR models included
miR-320 members as top predictors of fast-progressors and yielded AUC ranging from 82.6
to 91.9, representing good accuracy.
Conclusion: The miR-320 family is associated with fast-progressing radiographic knee OA and
merits further investigation as potential biomarkers and mechanistic drivers of knee OA.
Keywords: epigenetics, knee OA progression, longitudinal, noncoding RNAs, phenotyping,
prognostic biomarkers, sequencing
Received: 9 September 2021; revised manuscript accepted: 7 February 2022.

Introduction
Characterizing disease phenotypes remains an
outstanding challenge for osteoarthritis (OA), particularly for early stages of disease and for rapid
disease progression.1 Although biochemical (e.g.
collagen breakdown products) and imaging (e.g.
magnetic resonance imaging) biomarkers have

been explored for OA, these markers typically
become robust in established disease. The ability
to identify patients with early-stage and fastprogressing OA would support investigation of
disease mechanisms, delivery of preventive interventions, and recruitment to clinical trials, and
therefore is essential to advance the field.
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Unfortunately, there are currently no validated
methods for detecting early-stage or fast-progressing
knee OA, but there is promise in exploring circulating microRNAs.
MicroRNAs have emerged as powerful candidate
biomarkers for musculoskeletal diseases (e.g. osteoporosis)2,3 and are known to play important mechanistic roles in OA.4,5 These small, stable, noncoding
RNA molecules can be comprehensively profiled
in liquid biopsies using microRNA-sequencing.6
Sequencing offers advantages with respect to sensitive and specific detection of microRNAs, especially compared with previous techniques such as
microarrays which are limited to semi-quantification of preselected microRNAs. Recent sequencing
studies in blood identified differentially expressed
microRNAs in OA versus controls and in earlystage versus late-stage radiographic knee OA.7–10
Among these, a well-powered study revealed a signature of seven circulating microRNAs to be associated with early-stage radiographic knee OA.8
However, sequencing remains to be applied to
large-scale longitudinal cohorts to identify microRNAs that are associated with disease progression.
The purpose of this study is to apply our method
for microRNA-sequencing6 to identify circulating
microRNAs that are associated with radiographic
knee OA progression. We hypothesize that unique
microRNAs in plasma are associated with fastprogressing radiographic knee OA as compared
with slow-progressing and non-progressing radiographic knee OA. To test this hypothesis, we leverage the Osteoarthritis Initiative (OAI) which is
a well-characterized knee OA cohort with imaging, biospecimens, and clinical data available
from baseline to 10-year follow-up, with ongoing
collection.11 We apply a data-driven strategy to
define groups that advance from early to late
stages of radiographic knee OA, then perform
microRNA-sequencing at both baseline and
4-year follow-up in the same participants to identify circulating microRNAs that are differentially
expressed over time (Figure 1). These micro
RNAs may be clinically relevant as potential biomarkers and/or mechanistic drivers of disease.
Methods
OAI cohort
The OAI includes participants with varying disease trajectories that can be defined based on
established features such as Kellgren–Lawrence
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(KL) radiographic grades for knee OA severity.12
From among the 1926 participants in the OAI
with KL grades 0/1 at baseline, we used literature
recommendations to guide our selection of a sample size of at least 20 participants per group which
can reliably detect a 1.5-fold change in microRNA expression with a power of 80%.13 Based on
individual KL-grade trajectories over 8 years,
fast-progressors were defined as participants who
increased to KL 3/4 by 4-year follow-up (N = 20).
Slow-progressors were defined by KL 0/1 at baseline and 4-year follow-up, with KL 2/3/4 by 8-year
follow-up (N = 35). Non-progressors remained at
KL 0/1 throughout the 8-year follow-up and
N = 51 were selected using propensity score
methods. The OAI cohort is described in detail
at https://nda.nih.gov/oai and has been approved
by the Institutional Review Board for the
University of California, San Francisco (FWA
approval # 00000068; IRB approval # 10-00532),
and its affiliates. The following OAI datasets were
used: XRay[00-10], AllClinical[00-10], Kxr_sq_
bu[00-10], Enrollees, Biomarkers[00-10], and
Outcomes99. All participants provided written
informed consent to the OAI.
MicroRNA-sequencing
Frozen aliquots of 200 µL plasma collected at baseline (N = 106) and 4-year follow-up (N = 102; 4
samples were not available from the OAI) were
obtained from the OAI and stored at −80°C until
use. After thawing on ice, RNA was isolated using
the miRNeasy Serum/Plasma Advanced kit
(QIAGEN, Hilden, Germany) and microRNA
libraries were created with the QIAseq miRNA
Library kit (QIAGEN, Hilden, Germany). This
protocol is described in detail in our previous publication.8 Single-end 76-base sequencing on the
Illumina NextSeq550 platform was performed to
an average depth of 11.6 million (± 2.6 million
standard deviation) reads per sample. Sequencing
data were deposited in the Gene Expression
Omnibus database under accession number
GSE183188.
Bioinformatics
Quality control of sequencing data (e.g. Q
score ⩾ 30), reference-based alignment, counts
generation, and novel microRNA discovery14
were performed as previously described.6,8 No
samples were excluded from the present analysis
due to insufficient data quality. For microRNAs
shortlisted by differential expression (DE)
journals.sagepub.com/home/tab
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Figure 1. Schematic overview of study design. Participants selected from the Osteoarthritis Initiative (OAI)
cohort were characterized by the rate of radiographic knee osteoarthritis progression and plasma samples
collected at baseline and 4-year follow-up were subjected to microRNA (miRNA)-sequencing. Created with
BioRender.com.

analyses, predicted target genes were retrieved
from mirDIP version 4.1 (http://ophid.utoronto.
ca/mirDIP).15 Pathway enrichment analysis was
performed for each set of targets using pathDIP 4
API in R 4.0.3.16 From the pathways common
among at least three of four lists, the gene-pathway links were further investigated. Protein interactions for the gene targets were retrieved from
Integrative Interactions Database (IID), version
2021-05 (http://ophid.utoronto.ca/iid).17 The
network was visualized using NAViGaTOR, version 3.0.16,18 and exported to Adobe Illustrator,
version 26.0.2, to be finalized with legends.
Statistical analysis
DE analyses were performed at baseline and
4-year follow-up using negative binomial models
journals.sagepub.com/home/tab

cross-sectionally and a negative binomial mixed
model longitudinally.19,20 A propensity score constructed using age, sex, body mass index (BMI),
Western Ontario and McMaster Univer
sities
Osteoarthritis Index (WOMAC)21 and arthroscopy status (whether the participant underwent
arthroscopy prior or during the 8-year follow-up)
was introduced in the models as a covariate; additionally, the cross-sectional models were adjusted
for sequencing batch. MicroRNAs with false discovery rate (FDR) < 0.05 were considered in
penalized logistic regression (PLR) models for
each of the studied pairs (fast- versus slow-progressors, fast- versus non-progressors, and slowversus non-progressors) to determine their
predictive performance.22 PLR hyperparameters
were tuned using threefold 50-repeated crossvalidation with Cohen’s kappa as a performance
3
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measure under the ‘one-SE’ rule for model selection. Resulting microRNA-based models were
benchmarked against clinicodemographics-only
models using area under the receiver operating
characteristic curve (AUC).
Results
Characterizing participants by rate of
radiographic knee OA progression
Using a data-driven phenotyping approach, we
characterized the rate of radiographic knee OA
progression in 106 participants and identified
three distinct groups (Figure 2(a)). By 4-year
follow-up, fast-progressors exhibited KL 3/4
(N = 20), whereas slow-progressors remained at
KL 0/1 and only exhibited KL 2/3/4 by 8-year
follow-up (N = 35). Non-progressors remained at
KL 0/1 through to 8-year follow-up (N = 51).
Exploring clinicodemographic factors across
groups, differences were found in worsening total
WOMAC scores from baseline to 4-year followup and arthroscopy status (Table 1). More slowprogressors (42.9%) showed worsening WOMAC
score compared with non-progressors (17.6%),
despite both groups being KL 0/1 at 4-year follow-up. Furthermore, more fast-progressors and
slow-progressors underwent arthroscopy as compared with non-progressors, suggesting that
our definition of non-progressors was internally
consistent.
Identifying microRNAs associated with fastprogressing knee OA
Following microRNA-sequencing, we identified
532 and 411 microRNAs at baseline and 4-year
follow-up with greater than 10 counts-per-million
in at least two samples among 106 and 102 samples, respectively. Cross-sectional DE analyses
comparing the three groups pairwise within each
time-point identified 78 microRNAs at baseline
(Figure 2(b)) and 13 microRNAs at 4-year followup (Figure 2(c)) at FDR < 0.05 (Supplementary
File 1). Among these, 48 microRNAs at baseline
(Figure 2(d)) and 2 microRNAs at 4-year followup (Figure 2(e)) were upregulated when comparing
fast-progressors versus slow-progressors and nonprogressors, but not slow-progressors versus nonprogressors. The two microRNAs at 4-year
follow-up were hsa-miR-320c and hsa-miR-320d.
Notably, hsa-miR-320d was also among the 48
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microRNAs identified at baseline, along with
hsa-miR-320b and hsa-miR-320e (Figure 3(a)).
Therefore, hsa-miR-320d was significantly
increased among fast-progressors as compared
with both slow-progressors and non-progressors at
both baseline and 4-year follow-up. Longitu
dinal DE analyses identified seven microRNAs
between fast-progressors versus non-progressors
(FDR < 0.05) and no significant differences
between fast-progressors versus slow-progressors
or slow-progressors versus non-progressors
(Supplementary File 1). Our analysis for novel
microRNAs identified four sequences at baseline
and two at 4-year follow-up that were in > 50% of
fast-progressors, though the sequences were unique
to each time-point (Supplementary Figure 1).
Exploring the miR-320 family in fastprogressing knee OA
To determine the extent to which the DE microRNAs could distinguish fast-progressors from
slow-progressors and non-progressors, we built
and tested a PLR model per group comparison.
Using the comparison-specific DE microRNAs as
input, we found that AUCs for the microRNAbased models were greater than those based on
baseline age, sex, BMI, and WOMAC (Figure
3(b)). Of note, hsa-miR-320b/c/d/e were all
among the top 20 predictors for the fast-progressor versus non-progressor model (Supplementary
File 1). We then sought to predict the potential
function of the miR-320 family. Bioinformatic
analyses revealed that these miR-320 members
had both unique and overlapping putative target
genes and pathways, with 137 genes (Figure 4(a);
Supplementary File 2) and 14 pathways (Figure
4(b); Supplementary File 3) common to miR320b/c/d. Among these, four of the seven members of the 14-3-3 gene family comprising
YWHAZ,
YWHAQ,
YWHAH,
YWAHE,
YWHAB, YWHAG, and SFN were identified to
be annotated with eight common pathways each
(Figure 4(c); Supplementary File 4). We further
investigated the connection between the miR-320
family and the 14-3-3 gene family in mirDIP and
found that all four members of the miR-320 family were predicted to target all seven members of
the 14-3-3 gene family, albeit some predictions
had lower confidence (Figure 4(d)). In addition,
we found multiple protein–protein interactions
connecting all seven members of the 14-3-3 gene
family (Figure 4(d)).

journals.sagepub.com/home/tab
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Figure 2. Circulating microRNAs are differentially expressed among fast-progressors in the OAI cohort. (a)
Kellgren–Lawrence (KL) grade (XRKL) is plotted on the y-axis and time (years) is plotted on the x-axis. Dashed
lines connect individual trajectories; solid lines represent fitted second-order polynomials describing XRKL
as a function of time. Fast-progressors increase from KL grade 0/1 at baseline to KL 3/4 by 4-year follow-up.
Slow-progressors remain at KL 0/1 from baseline to 4-year follow-up then increase to KL 2/3/4 by 8-year
follow-up. Non-progressors remain at KL 0/1 through to 8-year follow-up. (b, c) Volcano plots showing changes
in microRNA expression resulting from cross-sectional analysis of fast-progressors versus slow-progressors,
fast-progressors versus non-progressors, and slow-progressors versus non-progressors at baseline (b) and
4-year follow-up (c). Red points indicate microRNAs showing statistically significant changes with a log2 fold
change (FC) of ±1 or more. (d, e) Venn diagrams showing unique and overlapping differentially expressed
microRNAs among each of the three comparisons performed at baseline (d) and 4-year follow-up (e).
NS, not significant.

Discussion
Leveraging the OAI cohort, we used a data-driven
approach to characterize three distinct disease
progression groups that provide greater phenotypic resolution than dividing participants into

journals.sagepub.com/home/tab

radiographic progressors versus non-progressors
alone. Applying microRNA-sequencing to samples from 106 participants at 2 time-points, we
identified circulating microRNAs that are associated with fast-progressing radiographic knee OA
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Table 1. Clinicodemographic characteristics of progression groups.
Non

Slow

Fast

N

51

35

20

Age, mean years (SD)

59.2 (9.2)

57.5 (8.4)

61.0 (8.1)

p-value

0.374

Age, N (% > 60 years)

20 (39.2)

10 (28.6)

11 (55.0)

0.153

Sex, N (% males)

13 (25.5)

9 (25.7)

7 (35.0)

0.696

8 (15.7)

2 (5.7)

4 (20.0)

0.247

Race, N (% non-white)
BMI, mean kg/m2 (SD)

28.8 (4.1)

29.2 (5.1)

28.5 (5.1)

BMI categories:

0.855
0.513

•• Healthy weight = 18.5–24.9 kg/m2, N (%)

10 (19.6)

7 (20.0)

5 (25.0)

•• Overweight = 25–29.9 kg/m2, N (%)

26 (51.0)

12 (34.3)

9 (45.0)

•• Obese = 30 + kg/m2, N (%)

15 (29.4)

16 (45.7)

6 (30.0)

WOMAC worseninga, N (% worsen)

9 (17.6)

15 (42.9)

6 (30.0)

0.038*

Arthroscopy, N (% yes)

3 (5.9)

12 (34.3)

6 (30.0)

0.002*

0.64 (0.22)

0.55 (0.25)

<0.001*

Propensity score, mean (SD)

0.43 (0.15)

Each factor was summarized across progression groups by their means (standard deviations) or counts (proportions) for
continuous or categorical factors, respectively. Differences among groups were ascertained using Welch (continuous) and
chi-square (categorical) tests.
BMI, body mass index; SD, standard deviation; WOMAC, Western Ontario and McMaster Universities Osteoarthritis
Index.
aTotal WOMAC score with worsening defined by an increase of 7 or more points from baseline to 4-year follow-up.
*Statistically significant.

over time, including members of the miR-320
family, which are predicted to target members of
the 14-3-3 gene family among other genes. While
future studies are required to externally validate
these findings in independent longitudinal knee
OA cohorts, our data suggest microRNAs may be
key molecular markers and mechanistic drivers of
fast-progressing knee OA.
Imaging and biochemical markers have been
explored as prognostic biomarkers in the OAI
cohort, yet are not currently in clinical use.23,24 As
these approaches require structural changes to
have occurred before markers can be detected,
opportunities for prevention are reduced. As epigenetic regulators of gene expression, microRNAs may appear earlier in disease pathogenesis
and therefore could precede irreversible structural damage in knee OA. This is a strength of
microRNAs as biomarkers, and our data suggest

6

unique combinations of microRNAs offer strong
predictive ability. Through use of the OAI cohort,
our microRNA-sequencing data can be integrated
with other imaging and biochemical data to support discovery of composite biomarkers for OA.
To note limitations of this study, we characterized OA based on radiographic severity (i.e. KL
grade) alone. Future studies may explore other
structural (e.g. joint space narrowing) or symptomatic (e.g. pain) features that typify knee OA. We
also selected a subset of the OAI cohort enriched
for participants who progressed from early-stage
radiographic knee OA at baseline (KL 0/1) to
late-stage radiographic knee OA by 8-year followup (KL 3/4). Future studies with larger sample
sizes could investigate broader and alternative
definitions of fast-progressing knee OA (e.g. KL 2
to KL 4 in 4 years) while accounting for confounders such as comorbidities.

journals.sagepub.com/home/tab
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Figure 3. MiR-320 family members are distinguishing factors of fast-progressing knee OA. (a) Log2 fold changes for members of
the miR-320 family identified as differentially expressed at FDR < 0.05 in at least one comparison at baseline and 4-year follow-up.
(b) ROC curves comparing models using baseline clinicodemographic variables alone (orange) including age (continuous), sex, BMI
(continuous), and WOMAC (continuous) against microRNA-based models (green) from each comparison.
NS, not significant.

We report four of the five members of the miR-320
family25 to be associated with fast-progressing radiographic knee OA, a family of microRNAs our
predictions show to have both unique and overlapping gene targets. Previous studies suggest miR320a and miR-320c protect against OA cartilage
degeneration,26–28 potentially through downregulation of the Wnt signaling pathway.27,29 In addition,
plasma miR-320a along with miR-98-5p was
found to distinguish between neuropathic and
nociceptive musculoskeletal pain.30 Our data indicate miR-320d is upregulated in fast-progressors
versus both slow-progressors and non-progressors
at both baseline and 4-year follow-up, suggesting it
is associated with fast-progressing knee OA over
time and may have mechanistic functions through
regulation of its targets, including the 14-3-3 gene
family.
The 14-3-3 gene family comprises seven conserved protein isoforms which function to regulate

journals.sagepub.com/home/tab

signal transduction.31 Members of this family have
been explored as biomarkers and mechanistic
drivers of rheumatoid arthritis (RA)32 and OA.33
Of the seven isoforms, YWHAH and YWHAG
were detected in synovial fluid from inflammatory
joint disease patients, and YWHAH was elevated
in the serum compared with healthy controls.34,35
Furthermore, YWHAH was found to correlate
with other biomarkers of RA, and like YWHAE
could induce inflammatory factors and signaling
pathways linked to joint damage.36,37 Given the
observed upregulation of miR-320 family members in fast-progressing radiographic knee OA,
members of the 14-3-3 gene family would likely
be downregulated in a direct regulatory relationship. Taken together, our data suggest nuanced
interactions among individual miR-320 and
14-3-3 family members may be a mechanism for
fine-tuning signal transduction, a hypothesis that
merits further investigation for its potential role in
fast-progressing knee OA.
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Figure 4. MiR-320 family members are potential mechanistic players in fast-progressing knee OA. (a) Unique and overlapping
mirDIP gene targets for four members of the miR-320 family, filtered for top 1%. (b) Unique and overlapping pathways for four
members of the miR-320 family, filtered for p < 0.01. (c) Number of common enriched pathways (x-axis) with which the gene targets
(y-axis) are annotated. (d) Predicted targeting of the 14-3-3 gene family by the miR-320 family using all mirDIP results. Edges with
arrows denote the score class with V = very high, H = high, M = medium, and L = low according to the legend. Blue edges denote
protein–protein interactions (PPIs) from IID.
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